What the FDA labels say about taking them together
Lenalidomide and warfarin
Lenalidomide's FDA label of March 24, 2023 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name lenalidomide. The lenalidomide label: “Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.”
Check it at the source: the lenalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the lenalidomide label say about warfarin?
Lenalidomide label, drug interactionsClose monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.
Source: FDA drug label (Revlimid), NDA021880 (Bristol Myers Squibb), as published by Celgene Corporation, effective March 24, 2023 (SPL set 5fa97bf5-28a2-48f1-8955-f56012d296be), via openFDA; the full label on DailyMed
What does the warfarin label say about lenalidomide?
Warfarin's label (effective May 29, 2026) does not name lenalidomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lenalidomide | Warfarin | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma, Anemia | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once